" class="no-js "lang="en-US"> Concord Health Partners - Medtech Alert
Thursday, October 03, 2024

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Concord Health Partners | Pharmtech Focus

Concord Health Partners

About Concord Health Partners

Concord Health Partners

Concord Health Partners is a healthcare focused investment firm with a strategic model that optimizes the alignment of interests between investors and portfolio companies. Concord is primarily focused on investing in healthcare companies that have the potential to enhance the value of care through products, services, technologies and solutions that lower costs, improve quality and/or expand access to care.

Related Story

Appointments

 Concord Health Partners Adds Healthcare Private Equity Veteran Robert Schulz as Managing Director | Pharmtech Focus

Concord Health Partners Adds Healthcare Private Equity Veteran Robert Schulz as Managing Director

September 23 2022

Concord Health Partners (“Concord” or the “Firm”), a healthcare focused investment firm, today announced that […]

Fundraising

 Concord Health Partners Completes Final Close of Concord Innovation Fund II with Commitments of $150 Million | Pharmtech Focus

Concord Health Partners Completes Final Close of Concord Innovation Fund II with Commitments of $150 Million

September 20 2022

Concord Health Partners (“Concord” or the “Firm”), a healthcare focused investment firm, today announced the […]

Appointments

 Concord Health Partners Expands Senior Team & Opens Nashville Office | Pharmtech Focus

Concord Health Partners Expands Senior Team & Opens Nashville Office

July 15 2022

Concord Health Partners (“Concord” or the “Firm”), a healthcare focused investment firm, today announced that […]

Appointments

 Concord Health Partners Adds Healthcare Veteran Brian Gragnolati as Executive Partner | Pharmtech Focus

Concord Health Partners Adds Healthcare Veteran Brian Gragnolati as Executive Partner

July 12 2022

Concord Health Partners (“Concord” or the “Firm”), a healthcare focused investment firm, today announced that […]